{"id":"insulin-glargine-u100","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin glargine is a recombinant human insulin analog modified to have an extended duration of action (up to 24 hours). It binds to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. The U100 formulation contains 100 units per milliliter and is designed to provide steady basal insulin coverage for patients with diabetes.","oneSentence":"Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and reduce blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:14.757Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07076199","phase":"PHASE3","title":"A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-08-11","conditions":"Diabetes Mellitus, Type 1","enrollment":877},{"nctId":"NCT05834868","phase":"PHASE3","title":"Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2022-05-06","conditions":"Type 2 Diabetes","enrollment":1040},{"nctId":"NCT07282054","phase":"PHASE3","title":"Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2022-04-13","conditions":"Type 1 Diabetes","enrollment":550},{"nctId":"NCT06767735","phase":"PHASE3","title":"A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-02-17","conditions":"Diabetes","enrollment":580},{"nctId":"NCT06767761","phase":"PHASE3","title":"A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial Insulin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-02-18","conditions":"Diabetes","enrollment":580},{"nctId":"NCT05514535","phase":"PHASE3","title":"A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-08-29","conditions":"Diabetes Mellitus, Type 2, Obesity","enrollment":568},{"nctId":"NCT06340854","phase":"PHASE3","title":"A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-04-19","conditions":"Diabetes, Type 2","enrollment":429},{"nctId":"NCT05462756","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-08-11","conditions":"Type 2 Diabetes, Type 2 Diabetes Treated With Insulin","enrollment":730},{"nctId":"NCT06107153","phase":"PHASE3","title":"Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control","status":"COMPLETED","sponsor":"University of Basrah","startDate":"2023-11-01","conditions":"Type2diabetes","enrollment":243},{"nctId":"NCT03723772","phase":"PHASE1","title":"A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-11-29","conditions":"Diabetes Mellitus, Type 1","enrollment":66},{"nctId":"NCT06607224","phase":"NA","title":"Effect of the Use of Continuous Glucose Monitoring Versus Standard Glycemic Control in Hospitalized Patients with Type 2 Diabetes.","status":"COMPLETED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2022-01-10","conditions":"Diabetes Mellitus Type 2, Hospitalization","enrollment":40},{"nctId":"NCT03874715","phase":"PHASE3","title":"Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-03-11","conditions":"Type 1 Diabetes Mellitus","enrollment":210},{"nctId":"NCT04537923","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-10-19","conditions":"Type 2 Diabetes","enrollment":1428},{"nctId":"NCT03945656","phase":"PHASE1","title":"A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-05-07","conditions":"Diabetes Mellitus, Type 2","enrollment":43},{"nctId":"NCT03689374","phase":"PHASE3","title":"A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2","enrollment":2274},{"nctId":"NCT03668808","phase":"PHASE4","title":"Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.","status":"COMPLETED","sponsor":"Sansum Diabetes Research Institute","startDate":"2018-11-16","conditions":"Diabetes Mellitus, Type 1","enrollment":25},{"nctId":"NCT02967224","phase":"PHASE4","title":"A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to \"Standard of Care\" Basal Insulins in Insulin Naïve Patients Initiating Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-05","conditions":"Diabetes Mellitus, Type 2","enrollment":705},{"nctId":"NCT02967211","phase":"PHASE4","title":"A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to \"Standard of Care\" Basal Insulin in Patients Already Using Basal Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-12-21","conditions":"Diabetes Mellitus, Type 2","enrollment":609},{"nctId":"NCT03336528","phase":"PHASE4","title":"Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-01-02","conditions":"Type 2 Diabetes","enrollment":180},{"nctId":"NCT02688933","phase":"PHASE4","title":"A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-05","conditions":"Type 1 Diabetes Mellitus","enrollment":638},{"nctId":"NCT01499082","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-12","conditions":"Type 2 Diabetes Mellitus","enrollment":807},{"nctId":"NCT01499095","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-12","conditions":"Type 2 Diabetes Mellitus","enrollment":811},{"nctId":"NCT03922750","phase":"PHASE2","title":"A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-05-09","conditions":"Diabetes Mellitus, Type 2","enrollment":154},{"nctId":"NCT03951805","phase":"PHASE2","title":"A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-05-09","conditions":"Diabetes Mellitus, Type 2","enrollment":205},{"nctId":"NCT03766854","phase":"PHASE1","title":"A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a Week","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-12-07","conditions":"Diabetes Mellitus, Type 1","enrollment":24},{"nctId":"NCT03687827","phase":"PHASE4","title":"A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-10-02","conditions":"Diabetes Mellitus, Type 2","enrollment":498},{"nctId":"NCT04484779","phase":"NA","title":"A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-07-14","conditions":"Type 1 Diabetes, Type 2 Diabetes","enrollment":67},{"nctId":"NCT04692415","phase":"PHASE4","title":"Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors","status":"COMPLETED","sponsor":"University of Split, School of Medicine","startDate":"2018-12-15","conditions":"Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT02752412","phase":"PHASE3","title":"Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-17","conditions":"Type 2 Diabetes Mellitus","enrollment":513},{"nctId":"NCT03349840","phase":"PHASE4","title":"Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan","status":"TERMINATED","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2018-01-07","conditions":"Type2 Diabetes","enrollment":273},{"nctId":"NCT03013985","phase":"PHASE4","title":"Glargine U300 Hospital Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2017-05-17","conditions":"Type 2 Diabetes","enrollment":247},{"nctId":"NCT02320721","phase":"PHASE3","title":"Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":1014},{"nctId":"NCT03214380","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-07-14","conditions":"Type 2 Diabetes Mellitus","enrollment":933},{"nctId":"NCT04237493","phase":"PHASE4","title":"Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan","status":"COMPLETED","sponsor":"University of Jordan","startDate":"2017-02-14","conditions":"Diabetes Mellitus, Type 2","enrollment":687},{"nctId":"NCT02197520","phase":"PHASE1","title":"A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-07","conditions":"Diabetes Mellitus, Type 2","enrollment":24},{"nctId":"NCT02058160","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":736},{"nctId":"NCT02955953","phase":"PHASE1","title":"A Study Comparing Two Formulations of Insulin Glargine in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-11-14","conditions":"Healthy","enrollment":127},{"nctId":"NCT01683266","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-09","conditions":"Type 1 Diabetes Mellitus","enrollment":549},{"nctId":"NCT01676220","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Type 2 Diabetes Mellitus","enrollment":878},{"nctId":"NCT01658579","phase":"PHASE2","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Type 1 Diabetes Mellitus","enrollment":59},{"nctId":"NCT02201199","phase":"PHASE1","title":"Single Dose Clamp Study To Compare Concentration/Time Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With Lantus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-08","conditions":"Type 1 Diabetes Mellitus","enrollment":36},{"nctId":"NCT01146678","phase":"PHASE1","title":"Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-06","conditions":"Type 1 Diabetes Mellitus","enrollment":22}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABDOMINAL PAIN UPPER"},{"count":1,"reaction":"ACUTE KIDNEY INJURY"},{"count":1,"reaction":"AMYLASE INCREASED"},{"count":1,"reaction":"FATIGUE"},{"count":1,"reaction":"INTERNATIONAL NORMALISED RATIO INCREASED"},{"count":1,"reaction":"LACTIC ACIDOSIS"},{"count":1,"reaction":"LIPASE INCREASED"},{"count":1,"reaction":"METABOLIC ACIDOSIS"}],"_approvalHistory":[],"publicationCount":130,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Basaglar","Lantus","HOE901; Lantus"],"phase":"marketed","status":"active","brandName":"Insulin glargine U100","genericName":"Insulin glargine U100","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and reduce blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}